MBX Biosciences, Inc. (NASDAQ:MBX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

MBX Biosciences, Inc. (NASDAQ:MBX) has earned an average rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and eleven have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $50.20.

Several brokerages have issued reports on MBX. Wall Street Zen upgraded MBX Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Barclays initiated coverage on MBX Biosciences in a research note on Tuesday, January 27th. They set an “overweight” rating and a $66.00 target price for the company. Guggenheim lifted their price target on shares of MBX Biosciences from $77.00 to $88.00 and gave the company a “buy” rating in a research note on Friday, January 16th. The Goldman Sachs Group assumed coverage on shares of MBX Biosciences in a report on Thursday, December 4th. They issued a “sell” rating and a $18.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of MBX Biosciences in a report on Thursday, January 22nd.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of MBX. UBS Group AG grew its holdings in shares of MBX Biosciences by 363.1% during the fourth quarter. UBS Group AG now owns 281,212 shares of the company’s stock worth $8,869,000 after buying an additional 220,487 shares in the last quarter. Vanguard Group Inc. boosted its position in MBX Biosciences by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 1,817,811 shares of the company’s stock worth $57,334,000 after acquiring an additional 140,449 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of MBX Biosciences by 206.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 15,317 shares of the company’s stock worth $483,000 after acquiring an additional 10,317 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of MBX Biosciences in the fourth quarter valued at approximately $28,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of MBX Biosciences in the fourth quarter valued at approximately $69,000.

MBX Biosciences Trading Up 0.4%

MBX opened at $39.22 on Wednesday. The stock has a fifty day moving average price of $33.76. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of -16.41 and a beta of 0.87. MBX Biosciences has a twelve month low of $4.81 and a twelve month high of $44.89.

MBX Biosciences (NASDAQ:MBX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.10.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.